

regions (HCDR1-HCDR2-HCDR3/LCDR1-LCDR2-LCDR3) having the amino acid sequences of: (i) SEQ ID NOS:4-6-8/SEQ ID NOS:12-14-16; (ii) SEQ ID NOS:20-22-24/SEQ ID NOS:28-30-32; (iii) SEQ ID NOS:36-38-40/SEQ ID NOS:44-46-48; or (iv) SEQ ID NOS:52-54-56/SEQ ID NOS:60-62-64.

30. The pharmaceutical formulation of claim 1, wherein said human antibody that specifically binds to hIL-6R comprises heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pairs selected from the group consisting of: (i) SEQ ID NOS:2/10; (ii) SEQ ID NOS:18/26; (iii) SEQ ID NOS:34/42; and (iv) SEQ ID NOS:50/58.

31. A pharmaceutical formulation comprising: (i) about 175 mg/mL of a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R), wherein said antibody comprises a heavy chain and light chain variable region (HCVR/LCVR) amino acid sequence pair of SEQ ID NOS:18/26; (ii) about 25 mM histidine; (iii) about 5% sucrose; (iv) about 0.2% polysorbate 20; and (v) about 50 mM arginine.

* * * * *